Core Viewpoint - Criteo S.A. is set to transfer its legal domicile from France to Luxembourg and replace its American Depositary Shares (ADSs) structure with ordinary shares to be directly listed on Nasdaq, aiming to enhance shareholder value and align with long-term strategic goals [1][2][4]. Group 1: Corporate Actions - The Board of Directors has approved the proposed transfer of the Company's legal domicile and the change in share structure [1][2]. - A general meeting of shareholders is scheduled for February 27, 2026, to obtain approval for the Conversion and related proposals [2][3]. - The record date for ordinary shareholders to vote is set for February 25, 2026, while the record date for ADS holders is January 20, 2026 [3]. Group 2: Strategic Intent - The Chairman of the Board expressed that the move is intended to unlock significant shareholder value by streamlining corporate structure and enhancing capital management flexibility [2]. - Following the Conversion, Criteo plans to pursue a potential redomiciliation from Luxembourg to the United States, contingent on the Board's assessment of its benefits [4]. Group 3: Company Overview - Criteo operates as a global platform connecting the commerce ecosystem, leveraging AI-powered advertising to access over $1 trillion in annual commerce sales [5]. - The Company serves a diverse client base, providing technology and insights necessary for performance and growth in the digital commerce space [5].

Core Viewpoint - AtaiBeckley Inc. has successfully completed its redomiciliation from a Netherlands company to a U.S. entity incorporated in Delaware, aiming to enhance operational efficiency and align with its U.S. shareholder base [1][2][3] Group 1: Redomiciliation Details - The redomiciliation was approved by approximately 99% of votes at the extraordinary general meeting on November 4, 2025 [1] - The exchange of shares was conducted on a one-for-one basis, with former shareholders of Atai Beckley N.V. now holding shares in AtaiBeckley Inc., which continues to trade on NASDAQ under the symbol "ATAI" [2] Group 2: Expected Benefits - The company anticipates that the redomiciliation will lead to cost savings, alignment with its U.S. listing, simplification of corporate structure, and reduced administrative burdens for both the company and its investors [3] Group 3: Company Overview - AtaiBeckley is a clinical-stage biopharmaceutical company focused on developing rapid-acting and convenient mental health treatments, formed through the merger of ATAI Life Sciences N.V. and Beckley Psytech Limited in November 2025 [4] - The company's pipeline includes therapies for treatment-resistant depression and social anxiety disorder, with several candidates currently in Phase 2 clinical development [4]